(vianews) - medistim (medi.ol) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| medistim (medi.ol) | kr189.00 | 2.21% | 32.37% |
| ipsen (ipn.pa) | €107.00 | 1.08% | 12.52% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. medistim (medi.ol)
2.21% forward dividend yield and 32.37% return on equity
medistim asa develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the united states, europe, asia, and internationally. it offers miraq cardiac, a system that combines ultrasound imaging and transit time flow measurement (ttfm) in a single system for cardiac surgery; miraq vascular, a system that combines ultrasound imaging and transit ttfm in a single system for vascular surgery; and imaging probes for intraoperative use. the company also provides various flow probes, such as quickfit ttfm probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; vascular ttfm probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. in addition, it distributes and sells third party medical equipment. the company was incorporated in 1984 and is headquartered in oslo, norway.
earnings per share
as for profitability, medistim has a trailing twelve months eps of kr6.4.
pe ratio
medistim has a trailing twelve months price to earnings ratio of 29.53. meaning, the purchaser of the share is investing kr29.53 for every norwegian krone of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 32.37%.
more news about medistim.
2. ipsen (ipn.pa)
1.08% forward dividend yield and 12.52% return on equity
ipsen s.a. operates as a biopharmaceutical company worldwide. the company provides drugs in the areas of oncology, neuroscience, and rare diseases. its product pipeline comprises cabometyx + atezolizumab, which is in phase iii clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and taverik, which is in phase iii for the treatment of second line follicular lymphoma; bylvay, which is in phase iii for the treatment of biliary atresia; dysport, which is in phase iii clinical trial for the treatment of chronic and episodic migraine; fidrisertib, which is in phase ii clinical trial for the treatment of fibrodysplasia ossificans progressiva; elafibranor, which is in phase ii for the treatment of primary sclerosing cholangitis, as well as ipn60250; ipn10200, which is in phase ii for the treatment of longer-acting neurotoxin aesthetics and therapeutics; ipn60210, which is in phase i clinical trial for the treatment of relapsed/refractory multiple myeloma; and ipn60260 for the treatment of viral cholestatic disease and is in phase i clinical trial. the company also offers somatuline, decapeptyl, cabometyx, onivyde, tazverik, and other oncology products; dysport and other neurosciences products; and bylvay, nutropinaq, increlex, and sohonos for rare diseases. the company was founded in 1929 and is based in boulogne-billancourt, france.
earnings per share
as for profitability, ipsen has a trailing twelve months eps of €7.4.
pe ratio
ipsen has a trailing twelve months price to earnings ratio of 14.46. meaning, the purchaser of the share is investing €14.46 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.52%.
yearly top and bottom value
ipsen's stock is valued at €107.00 at 01:30 est, way under its 52-week high of €130.70 and way above its 52-week low of €94.85.
volume
today's last reported volume for ipsen is 20832 which is 72.1% below its average volume of 74668.
dividend yield
as maintained by morningstar, inc., the next dividend payment is on jun 2, 2023, the estimated forward annual dividend rate is 1.2 and the estimated forward annual dividend yield is 1.08%.
more news about ipsen.